Variant report

Variant	esv14982
Chromosome Location	chr21:47052971-47054551
allele	n/a
Outlinks	Ensembl UCSC

Chromatin state
Related regulatory elements
Target genes
Other information

No.	Distal block	Cell Line	Cell type	Cell Stage
1	chr21:47054503..47058217-chr21:47058461..47061717,3	K562	blood:
2	chr21:47044412..47047095-chr21:47051523..47054787,3	MCF-7	breast:

Extended variants
information (count: 113 )
Associated
traits (count: 36 )

Variant overlapped rSNPs/rCNVs (count:113 , 50 per page) page: 1 2 3

No.	Variant name	Chromosome position	Chromatin state	Related regulatory elements	Target genes	Extended variants	Associated traits
1	rs535121655	chr21:47052986-47052987	Weak transcription Bivalent Enhancer Enhancers Flanking Active TSS	n/a	n/a	Overlapped CNVs	n/a
2	rs567393347	chr21:47053053-47053054	Weak transcription Enhancers Flanking Active TSS	n/a	n/a	Overlapped CNVs	n/a
3	rs79828927	chr21:47053056-47053057	Weak transcription Enhancers Flanking Active TSS	n/a	n/a	Overlapped CNVs	n/a
4	rs146239747	chr21:47053063-47053064	Weak transcription Enhancers Flanking Active TSS	n/a	n/a	Overlapped CNVs	n/a
5	rs374385193	chr21:47053064-47053065	Weak transcription Enhancers Flanking Active TSS	n/a	n/a	Overlapped CNVs	n/a
6	rs72497638	chr21:47053072-47053073	Weak transcription Enhancers Flanking Active TSS	n/a	n/a	Overlapped CNVs	n/a
7	rs576298968	chr21:47053088-47053089	Weak transcription Enhancers Flanking Active TSS	n/a	n/a	Overlapped CNVs	n/a
8	rs537368885	chr21:47053094-47053095	Weak transcription Enhancers Flanking Active TSS	n/a	n/a	Overlapped CNVs	n/a
9	rs555683124	chr21:47053097-47053098	Weak transcription Enhancers Flanking Active TSS	n/a	n/a	Overlapped CNVs	n/a
10	rs573956401	chr21:47053102-47053103	Weak transcription Enhancers Flanking Active TSS	n/a	n/a	Overlapped CNVs	n/a
11	rs202192694	chr21:47053108-47053109	Weak transcription Enhancers Flanking Active TSS	n/a	n/a	Overlapped CNVs	n/a
12	rs142666745	chr21:47053110-47053111	Weak transcription Enhancers Flanking Active TSS	n/a	n/a	Overlapped CNVs	n/a
13	rs199742238	chr21:47053118-47053119	Weak transcription Enhancers Flanking Active TSS	n/a	n/a	Overlapped CNVs	n/a
14	rs546797477	chr21:47053132-47053133	Weak transcription Enhancers Flanking Active TSS	n/a	n/a	Overlapped CNVs	n/a
15	rs377652435	chr21:47053149-47053150	Weak transcription Enhancers Flanking Active TSS	n/a	n/a	Overlapped CNVs	n/a
16	rs62216075	chr21:47053153-47053154	Weak transcription Enhancers Flanking Active TSS	n/a	n/a	Overlapped CNVs	n/a
17	rs7275912	chr21:47053184-47053185	Weak transcription Enhancers Flanking Active TSS	n/a	n/a	Overlapped CNVs	n/a
18	rs60274885	chr21:47053194-47053195	Weak transcription Enhancers Flanking Active TSS	n/a	n/a	Overlapped CNVs	n/a
19	rs78515897	chr21:47053197-47053198	Weak transcription Enhancers Flanking Active TSS	n/a	n/a	Overlapped CNVs	n/a
20	rs111517444	chr21:47053227-47053228	Weak transcription Enhancers	n/a	n/a	Overlapped CNVs	n/a
21	rs75090328	chr21:47053238-47053239	Weak transcription Enhancers	n/a	n/a	Overlapped CNVs	n/a
22	rs546275532	chr21:47053239-47053240	Weak transcription Enhancers	n/a	n/a	Overlapped CNVs	n/a
23	rs375300129	chr21:47053248-47053249	Weak transcription Enhancers	n/a	n/a	Overlapped CNVs	n/a
24	rs75912427	chr21:47053255-47053256	Weak transcription Enhancers	n/a	n/a	Overlapped CNVs	n/a
25	rs78051092	chr21:47053266-47053267	Weak transcription Enhancers	n/a	n/a	Overlapped CNVs	n/a
26	rs79112626	chr21:47053269-47053270	Weak transcription Enhancers	n/a	n/a	Overlapped CNVs	n/a
27	rs78713807	chr21:47053286-47053287	Weak transcription Enhancers	n/a	n/a	Overlapped CNVs	n/a
28	rs79429599	chr21:47053307-47053308	Weak transcription Enhancers	n/a	n/a	Overlapped CNVs	n/a
29	rs71205884	chr21:47053334-47053335	Weak transcription Enhancers	n/a	n/a	Overlapped CNVs	n/a
30	rs564368204	chr21:47053337-47053338	Weak transcription Enhancers	n/a	n/a	Overlapped CNVs	n/a
31	rs373818343	chr21:47053359-47053360	Weak transcription Enhancers	n/a	n/a	Overlapped CNVs	n/a
32	rs71240731	chr21:47053375-47053376	Weak transcription Enhancers	n/a	n/a	Overlapped CNVs	n/a
33	rs13049632	chr21:47053382-47053383	Weak transcription Enhancers	n/a	n/a	Overlapped CNVs	n/a
34	rs74208552	chr21:47053385-47053386	Weak transcription Enhancers	n/a	n/a	Overlapped CNVs	n/a
35	rs75753326	chr21:47053392-47053393	Weak transcription Enhancers	n/a	n/a	Overlapped CNVs	n/a
36	rs71240732	chr21:47053403-47053404	Weak transcription Enhancers	n/a	n/a	Overlapped CNVs	n/a
37	rs71205885	chr21:47053423-47053424	Weak transcription Enhancers	n/a	n/a	Overlapped CNVs	n/a
38	rs370494251	chr21:47053432-47053433	Weak transcription Enhancers	n/a	n/a	Overlapped CNVs	n/a
39	rs13049251	chr21:47053444-47053445	Weak transcription Enhancers	n/a	n/a	Overlapped CNVs	n/a
40	rs368428808	chr21:47053454-47053455	Weak transcription Enhancers	n/a	n/a	Overlapped CNVs	n/a
41	rs113268944	chr21:47053460-47053461	Weak transcription Enhancers	n/a	n/a	Overlapped CNVs	n/a
42	rs13049340	chr21:47053471-47053472	Weak transcription Enhancers	n/a	n/a	Overlapped CNVs	n/a
43	rs35875403	chr21:47053473-47053474	Weak transcription Enhancers	n/a	n/a	Overlapped CNVs	n/a
44	rs373902783	chr21:47053482-47053483	Weak transcription Enhancers	n/a	n/a	Overlapped CNVs	n/a
45	rs113246323	chr21:47053491-47053492	Weak transcription Enhancers	n/a	n/a	Overlapped CNVs	n/a
46	rs531774304	chr21:47053521-47053522	Weak transcription Enhancers	n/a	n/a	Overlapped CNVs	n/a
47	rs372605795	chr21:47053529-47053530	Weak transcription Enhancers	n/a	n/a	Overlapped CNVs	n/a
48	rs543577061	chr21:47053535-47053536	Weak transcription Enhancers	n/a	n/a	Overlapped CNVs	n/a
49	rs13049371	chr21:47053540-47053541	Weak transcription Enhancers	n/a	n/a	Overlapped CNVs	n/a
50	rs375501889	chr21:47053560-47053561	Weak transcription Enhancers	n/a	n/a	Overlapped CNVs	n/a

Variant related diseases (count:36)

Disease	PMID	Source
Down syndrome	17576883	CNVD
Acute promyelocytic leukemia	19109227	CNVD
T-cell prolymphocytic leukemia	17713554	CNVD
Prostate cancer	19156837	CNVD
Basal cell lymphoma	17170743	CNVD
Follicular lymphoma	17170743	CNVD
Primary mediastinal b-cell lymphoma	17728785	CNVD
Basal cell lymphoma	16317097	CNVD
Diffuse large b-cell lymphoma	16317097	CNVD
Autism	22958593	CNVD
Schizophrenia	22958593	CNVD
Breast cancer	20668451	CNVD
Cancer	20668451	CNVD
Lung cancer	20668451	CNVD
Ovarian cancer	20668451	CNVD
Pancreas cancer	20668451	CNVD
Prostate cancer	20668451	CNVD
High-grade prostatic intraepithelial neoplasia	16573809	CNVD
Autism	18414403	CNVD
Gastrointestinal stromal cancer	19259404	CNVD
Breast cancer	17899364	CNVD
Prostate cancer	20473283	CNVD
Chordoma	18071362	CNVD
Cholangiocarcinoma	16830362	CNVD
Down syndrome	17334655	CNVD
Neuroticism	17667963	CNVD
Adenoid cystic carcinoma	18698036	CNVD
Autoimmune polyendocrine syndrome	18200029	CNVD
Prostate cancer	19363497	CNVD
Lung adenocarcinoma	17086460	CNVD
Lung cancer	17086460	CNVD
Olfactory neuroblastoma	18408657	CNVD
Salivary gland adenoid cystic carcinoma	17545515	CNVD
Multiple myeloma	16616336	CNVD
low-grade B-cell lymphoma tumor	18367492	CNVD
Breast cancer	21509527	CNVD

Chromatin state (count:37 , 50 per page) page: 1

No.	Chromosome Location	Chromatin state	Cell line	Tissue
1	chr21:47050400-47055800	Weak transcription	H1 Derived Mesenchymal Stem Cells	ES cell derived
2	chr21:47051200-47053200	Enhancers	Primary B cells from peripheral blood	blood
3	chr21:47051600-47053200	Flanking Active TSS	Thymus	Thymus
4	chr21:47052000-47053000	Flanking Active TSS	Fetal Thymus	thymus
5	chr21:47052200-47053000	Enhancers	Primary neutrophils fromperipheralblood	blood
6	chr21:47052400-47053000	Enhancers	Breast variant Human Mammary Epithelial Cells (vHMEC)	Breast
7	chr21:47052400-47053000	Enhancers	Dnd41	blood
8	chr21:47052600-47053200	Enhancers	Foreskin Keratinocyte Primary Cells skin02	Skin
9	chr21:47052600-47053200	Enhancers	Spleen	Spleen
10	chr21:47052600-47059000	Weak transcription	Primary T helper cells fromperipheralblood	blood
11	chr21:47052800-47053000	Bivalent Enhancer	Breast Myoepithelial Primary Cells	Breast
12	chr21:47052800-47053200	Enhancers	Esophagus	oesophagus
13	chr21:47052800-47053200	Enhancers	GM12878-XiMat	blood
14	chr21:47052800-47053200	Enhancers	HMEC	breast
15	chr21:47052800-47058000	Weak transcription	Primary T helper naive cells fromperipheralblood	blood
16	chr21:47052800-47058400	Weak transcription	Primary T cells from cord blood	blood
17	chr21:47053000-47054200	Enhancers	Fetal Thymus	thymus
18	chr21:47053000-47058000	Weak transcription	Dnd41	blood
19	chr21:47053200-47054200	Weak transcription	Thymus	Thymus
20	chr21:47053200-47054400	Weak transcription	Primary B cells from peripheral blood	blood
21	chr21:47053200-47054600	Weak transcription	GM12878-XiMat	blood
22	chr21:47053200-47055400	Weak transcription	Esophagus	oesophagus
23	chr21:47053200-47055800	Weak transcription	Spleen	Spleen
24	chr21:47054200-47054600	Active TSS	Thymus	Thymus
25	chr21:47054200-47055000	Flanking Active TSS	Fetal Thymus	thymus
26	chr21:47054400-47054600	Active TSS	Mesenchymal Stem Cell Derived Adipocyte Cultured Cells	ES cell derived
27	chr21:47054400-47054600	Flanking Bivalent TSS/Enh	Adipose Derived Mesenchymal Stem Cell Cultured Cells	ES cell derived
28	chr21:47054400-47054600	Flanking Bivalent TSS/Enh	Foreskin Fibroblast Primary Cells skin01	Skin
29	chr21:47054400-47054600	Flanking Bivalent TSS/Enh	Foreskin Fibroblast Primary Cells skin02	Skin
30	chr21:47054400-47054600	Bivalent Enhancer	Fetal Muscle Trunk	muscle
31	chr21:47054400-47054800	Active TSS	NHDF-Ad	bronchial
32	chr21:47054400-47055000	Active TSS	HSMMtube	muscle
33	chr21:47054400-47055200	Bivalent Enhancer	Breast Myoepithelial Primary Cells	Breast
34	chr21:47054400-47055200	Enhancers	HSMM	muscle
35	chr21:47054400-47055200	Enhancers	Osteobl	bone
36	chr21:47054400-47055400	Enhancers	Primary B cells from peripheral blood	blood
37	chr21:47054400-47056200	Enhancers	Gastric	stomach

The 2.0 version of rSNPBase

Variant report

Quick Search:

what's new

Quick links